News

In a recent study, patients with PBC experienced more muscle loss, itching and malnutrition than patients with other liver disorders.

The U.S. Food and Drug Administration gave accelerated approval for seladelpar to treat primary biliary cholangitis (PBC).

Changes in the gut microbiome configuration could negatively affect the response to ursodeoxycholic acid (UDCA) treatment in patients with primary biliary cholangitis (PBC), according to a recently published study in Med. “These findings suggest that baseline microbial composition may predict treatment response and offer novel insights into PBC pathogenesis,” the study concluded. UDCA represents first-line […]

Results from the first epigenome-wide association study of patients with PBC and PSC have been recently published.

A recent study showed improvement of the gut microbiota may be a critical aspect of PBC prevention and treatment.

Treatment with obeticholic acid (OCA) improved outcomes for primary biliary cholangitis (PBC) patients in a recent clinical trial.

A recent study found that some PBC patients face more barriers to care, leading to a delay in diagnosis and treatment.

A recent study showed irritable bowel syndrome (IBD) is a risk factor for primary biliary cholangitis (PBC).

A phase 2b clinical trial has shown positive preliminary results for volixibat intended for the treatment of PBC.

Ipsen’s Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of the PBC, according to a recent press release.